VK-2019
VK-2019 is an oral active, selective EBNA1 ((Epstein-Barr Nuclear Antigen 1) inhibitor and can be used for study of EBV-associated carcinomas[1].
Product Specifications
CAS Number
2044520-06-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EBV
Type
Reference compound
Related Pathways
Anti-infection
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vk-2019.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=C(C2=CC3=C(C=CN3)C=C2)C(C#CC4=CC=C(COC5CCOCC5)C=C4)=CC=C1)O
Molecular Formula
C29H25NO4
Molecular Weight
451.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Davis MT, et al. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. Biomed Chromatogr. 2024;38 (2) :e5775.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Imidazo[1,2-a]pyridine-6-boronic Acid](https://cdn.genprice.uk/products/572/1516996130553/imageurl/trc-i387548-250mg.webp)